Chapter 10. Does Intensive Glycaemic Management Reduce Morbidity and Mortality in Type 2 Diabetes?

  1. William H. Herman1,
  2. Ann Louise Kinmonth2,
  3. Nicholas J. Wareham3 and
  4. Rhys Williams4
  1. Amanda I. Adler

Published Online: 12 JAN 2010

DOI: 10.1002/9780470682807.ch10

The Evidence Base for Diabetes Care, Second Edition

The Evidence Base for Diabetes Care, Second Edition

How to Cite

Adler, A. I. (2010) Does Intensive Glycaemic Management Reduce Morbidity and Mortality in Type 2 Diabetes?, in The Evidence Base for Diabetes Care, Second Edition (eds W. H. Herman, A. L. Kinmonth, N. J. Wareham and R. Williams), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470682807.ch10

Editor Information

  1. 1

    Department of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI, USA

  2. 2

    General Practice and Primary Care Research Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

  3. 3

    MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK

  4. 4

    School of Medicine, Swansea University, Swansea, UK

Author Information

  1. MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK

Publication History

  1. Published Online: 12 JAN 2010
  2. Published Print: 19 FEB 2010

ISBN Information

Print ISBN: 9780470032749

Online ISBN: 9780470682807

SEARCH

Keywords:

  • intensive glycaemic management reducing morbidity and mortality in type 2 diabetes;
  • hyperglycaemia increasing risk of complications in type 2 diabetes;
  • microvascular complications to macrovascular complications and death;
  • blood glucose-lowering strategies in type 2 diabetes;
  • University Group Diabetes Program (UGDP);
  • Veterans Affairs Cooperative Study and Veterans Affairs Diabetes Trial (VADT);
  • blood glucose intensive treatment and worsening of diabetic complication prevention - Japanese study;
  • United Kingdom Prospective Diabetes Study (UKPDS);
  • prospective pioglitazone clinical trial in macrovascular events (PROactive) study;
  • Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Summary

This chapter contains sections titled:

  • Background

  • Blood glucose-lowering strategies in type 2 diabetes

  • Completed clinical trials

  • Ongoing clinical trials

  • Reducing weight using medications

  • Discussion

  • References